Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. (2017)
Attributed to:
Development of a novel, potent, safe, long-lasting lentivirus-based gene therapy for cystic fibrosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/thoraxjnl-2016-208406
PubMed Identifier: 27852956
Publication URI: http://europepmc.org/abstract/MED/27852956
Type: Journal Article/Review
Volume: 72
Parent Publication: Thorax
Issue: 2
ISSN: 0040-6376